|
Basic InformationMore InformationLatest NewsHIV No Barrier to Getting Liver Transplant, Study FindsImmune Cell Discovery May One Day Lead to Herpes Vaccine: StudyHalf of People With Hepatitis C Don't Complete Needed Tests: CDCNew Guidelines Suggest HIV Screening for All AdultsHIV 'Cure' Looks 'Promising,' Danish Scientists ContendSofosbuvir Shows Promise for Chronic Hepatitis C InfectionStudy Hints of Links Between HPV and Lung CancerCould Self-Testing Help Overcome HIV/AIDS Epidemic?Experimental Drug May Work Against Hepatitis CHIV Prevalence Is High Among High-Risk HeterosexualsCDC: 1 in 50 Poor, Straight Urban Americans Infected With HIVHIV Infection Linked to Risk of Acute Myocardial InfarctionHIV May Raise Risk of Heart AttackResearchers Describe 1st 'Functional Cure' of HIV in BabyU.S. AIDS-Relief Plan a Success, Report FindsMillions of Americans Have an STD: ReportCertain Skin Cancers More Common in HIV-Positive PeopleDrug Users Are 'Super-Spreaders' of Hepatitis C, Study FindsStudy Pinpoints Optimal Treatment Window for HIVGeneric Three-Pill HIV Regimen Could Result in Big SavingsSome HPV-Linked Cancers Rising in U.S.: ReportNew Pills Show Promise for Hepatitis CFulyzaq Approved for Diarrhea in People With HIV/AIDSSmoking Deadlier For HIV Patients Than Virus Itself: StudyKids With HIV at Risk of Heart Disease, Study SaysUse of Clinical Decision-Support System Can Improve HIV CareAmong Black Americans, HIV Takes a Greater TollNew HIV Infections Highest Among Urban Gay, Bisexual Men: CDCHIV Infections Continue to Hit Young Americans HardAIDS Deaths, New HIV Infections Continue to Drop WorldwideU.S. Task Force Backs HIV Screening for All 15 to 65Antiviral Therapy for Hepatitis C May Thwart Liver CancerHigh-Dose Vitamins Don't Halt HIV Progression, DeathExperimental Vaccine Might Help Women Already Infected With HPVMore Stomach, Esophageal Cancers Seen in AIDS Patients Than OthersScientists Probe How Some HIV Patients Resist AIDSImproved HIV Care Boosts Life Expectancy at Clinic, Study FoundAntiretrovirals Increasingly Used for HIV in the U.S.More Americans Get Effective HIV Treatment, Study SaysOnce-Daily Pill Approved to Treat HIVHepatitis C Treatment May Hamper Kids' GrowthGonorrhea Resistant to All But One Antibiotic: CDCNew Clues to How HIV Infects Body's CellsOnly 1 in 4 Americans With HIV Has Virus Under Control: CDCHIV Drug-Resistance Up in Resource-Limited SettingsAll HIV Patients Should Take Meds Early On, Experts Now SayMom's HIV Drugs May Pass to Baby in Womb, Breast-FeedingNot All HIV Patients in U.S. Show Same Characteristics: StudyHIV Racial Disparities Noted for Men Who Have Sex With MenVitamin B12 Improves Viral Response in Chronic Hepatitis C Questions and AnswersLinksBook Reviews |
| |
Adding Vitamin B12 to Standard Drugs Might Help Fight Hepatitis C
by -- Robert Preidt
Updated: Jul 18th 2012
WEDNESDAY, July 18 (HealthDay News) -- Taking vitamin B12 supplements may help boost the effectiveness of antiviral drugs for patients infected with hepatitis C virus, a new study suggests.
This effect was especially strong in patients whose infection was particularly tough to treat, note Italian researchers led by Dr. Gerardo Nardone of the University of Naples.
According to Nardone's team, the standard treatment of two drugs -- interferon (peg IFN) and ribavarin -- clears the virus in about 50 percent of patients infected with strain 1 of the virus and 80 percent of those infected with strains 2 or 3.
However, that means that the treatment still does not clear hepatitis C in about half of all patients infected with the virus or if the infection returns once treatment ends.
The new study included 94 patients with hepatitis C infection who were randomly assigned to receive standard treatment with antiviral drugs or standard treatment plus 5,000 micrograms of vitamin B12 every month for between six and 12 months.
The ability of the patients' bodies to clear the virus was assessed after one month and three months (dubbed a "rapid viral response"), at the end of treatment ("complete early viral response"), and six months after the end of treatment ("sustained viral response").
After one month of treatment, there was no difference in response between patients receiving standard treatment and those receiving standard treatment plus vitamin B12. However, patients receiving vitamin B12 showed significantly greater response at all of the other time points, particularly by six months after the end of treatment.
Overall, adding vitamin B12 to standard treatment strengthened the rate of long-term, sustained viral response by 34 percent, the researchers noted.
The investigators also found that the increased response associated with taking vitamin B12 was particularly strong in patients with the type 1 strain of hepatitis C and in those with higher levels of infection.
The addition of vitamin B12 to treatment with current antiviral drugs offers a safe and inexpensive option until new-generation antiviral drugs become available or if those new treatments are too expensive, the researchers concluded.
Two U.S. experts were more dubious as they weighed in on the findings.
Dr. David Bernstein is chief of the division of hepatology at North Shore University Hospital in Manhasset, N.Y. He noted that for patients with strains 2 and 3 of the virus, adding vitamin B12 "was not of any value."
As for patients with strain 1 of the virus, Bernstein said the standard of care is now a three-drug regimen of pegylated interferon plus ribavirin plus a protease inhibitor drug, not the two-drug regimen used in this study. So, "while the information presented in this study is interesting in genotype [strain] 1 patients . . . what would be more interesting would be the addition of vitamin B12 to the current standard of care therapy of pegylated interferon plus ribavirin plus a protease inhibitor," Bernstein said.
Dr. Peter Malet, director of the Center for Liver Diseases, and a hepatologist at Winthrop-University Hospital in Mineola, N.Y., agreed.
"This research is very preliminary; it needs to be confirmed or refuted by other studies," he said.
The study was published online July 17 in the journal Gut.
More information
The U.S. National Institute of Allergy and Infectious Diseases has more about hepatitis C.
This article: Copyright © 2012 HealthDay. All rights reserved. | 
